Article Figures & Data
Figures
- Abstract 3 Figure 1
- Abstract 5 Figure 1
- Abstract 21 Figure 1
Photographs of the patient demonstrating abnormal anterior abdominal subcutaneous fat deposition alongside
- Abstract 29 Figure 1
- Abstract 30 Figure 1
MRI Brain (Image A) shows multiple flow voids in right frontal lobe on axial T2 image consistent with arterio-venous malformation. In addition, there are multiple hyperintense T2 signal areas (arrows) in the white matter bilaterally. Post-contrast axial MRI brain image (Image B) shows multiple tortuous enhancing vessels (arrow) in the right frontal lobe arteriovenous malformation
- Abstract 32 Figure 1
- Abstract 48 Figure 1
- Abstract 50 Figure 1
MRCP and CTscan showing a large congenital choledochal cyst ∼3.8 cm, and common bile duct dilation ∼4 cm, respectively.
- Abstract 70 Figure 1
- Abstract 73 Figure 1
- Abstract 75 Figure 1
- Abstract 87 Figure 1
TEE image of a large mass at the junction of the right atrium and SVC
- Abstract 91 Figure 1
- Abstract 98 Figure 1
- Abstract 99 Figure 1
Brain MRI
- Abstract 112 Figure 1
PET scan showing metastatic nodule in right clavicular region
- Abstract 113 Figure 1
- Abstract 118 Figure 1
- Abstract 137 Figure 1
- Abstract 137 Figure 2
- Abstract 150 Figure 1
Lymph node biopsy showing regressed germinal centers and interfollicular marked plasmacytosis and vascular proliferation
- Abstract 184 Figure 1
- Abstract 188 Figure 1
- Abstract 204 Figure 1
- Abstract 217 Figure 1
- Abstract 249 Figure 1
- Abstract 261 Figure 1
- Abstract 272 Figure 1
Patient's contrast MRI T2 and FLAIR images showing ADEM lesions of the periventricular white matter and bilateral frontal gyri.
- Abstract 272 Figure 2
Patient's helical chest CT image showing right pulmonary artery embolism with subsegmental involvement of the left side.
- Abstract 275 Figure 1
Growth Curves for Femoral Vein and Artery Diamter by Body Surface Area.
- Abstract 279 Figure 1
- Abstract 283 Figure 1
Frozen Magna Valve
- Abstract 285 Figure 1
- Abstract 285 Figure 2
- Abstract 292 Figure 1
Number of subjects and relative mortality in EL and PD group
- Abstract 314 Figure 1
- Abstract 321 Figure 1
Circulating IAI inversely correlated with SNAPPE-II scores
- Abstract 327 Figure 1
- Abstract 330 Figure 1
Comparing Mortality among Black and White Infants
- Abstract 336 Figure 1
- Abstract 338 Figure 1
- Abstract 352 Figure 1
A. Renal artery with intimal fibrosis. B. Glomerulus with fibrin thrombi. C. Duplication of GBM.
- Abstract 353 Figure 1
Transverse view of CT urogram with contrast demonstrating extensive bilateral angiomyolipomas with evidence of left hydronephrosis.
Tables
- Abstract 6 Table 1
Primary Aldosteronism Non-Primary Aldosteronism LVM (g/m2) IVS (mm) LVM (g/m2) IVS (mm) UNa<200
(n=13)UNa≥200
(n=7)UNa<200
(n=13)UNa≥200
(n=7)UNa<200
(n=5)UNa≥200
(n=9)UNa<200
(n=5)UNa≥200
(n=9)Baseline 170.2 175.8 12.4 11.0 158.3 205.1 11.6 13.4 Difference between baseline, 3, and 6 month visits after addition of spironolactone Baseline to 3 months −34.8 −16.0* −1.5 0.1 −7.0 −33.2* −0.4 −0.7 Baseline to 6 months −52.0 −25.0* −1.4 0.5 −19.8 −40.5* 1.2 −1.4 * denotes statistical significance p<0.05
- Abstract 9 Table 1
PTH BNP 25OHD HFpEF 165.7±51.0 1369.1±383.4 21.2±2.5 HFrEF 89.7±13.0 1057.6±174.6 18.6±1.5 - Abstract 54 Table 1
Percent of Infants Observed or Identified with No risk on Three SIDS Prevention Level A recommendations
Level A Recommendations Observed
SafeFamily Map Question Family Map Report Safe Kappa Correlation Coeffiicient, r N 1. Back to sleep for every sleep 74.3% Do you place your baby on his/her back to sleep at night or during naps? 82.9% 0.58** 0.60 35 2. Room-sharing without bed-sharing is recommended 81.0% Do you co-sleep with your baby at night? (Reverse) 46.7% 036 0.47 30 3. Keep soft objects and loose bedding out of the crib 42.1% Which of the following do you have in your home? Crib/Bed filled with soft bedding or lots of stuffed toys (Reverse) 76.8% 0.10 0.17 38 **P<0.05
- Abstract 60 Table 1
All Groups Manual EZ-IO® Difference 95% CI p-value Time to Placement (Min) Mean ESI 1 5.17 (N=12) 11.14 (N=14) 5.97 1.556–10.397 0.010 Standard Deviation 4 6.21 - Abstract 60 Table 2
≤ 8kg Manual EZ-IO® Difference 95% CI p-value Time to Placement (min) Mean ESI 1 4.5 (N=10) 12.8 (N=5) 8.3 1.892–14.708 0.015 Standard Deviation 3.72 7 - Abstract 61 Table 1
CBC with Diff WBC: 4.53 x 10340% Segs, 26% Bands, 21 Lymphocyte, 11 Monocytes Creatinine, albumin, LFTs Cr 3.5 (baseline), Alb 3.4, AST 19, ALT 12, Alk Phos 210 C-RP, ESR C-RP 1.5, ESR 46 Urine Culture No growth Ulcer HSV stain/viral culture Negative Serum HSV,EBV, CMV PCR Negative Bacterial/Fungal Blood and Wound Cultures No growth - Abstract 100 Table 1
1/2014 6/2014 9/2014 LH 18.8 16.7 9.2 mIU/ml (1.3–10.5) FSH 23.0 8.8 8.7 mIU/ml (1.5–12.4) Estrogen 185 124 183 pg/ml (40.0–115) Estradiol – – 53 pg/ml (7.6–42.8) Testosterone, Total 1427 1328 1185 ng/dL (250–1100) Testosterone, Free 139 7.5 15.8 pg/mL (8.7–25.1) MRI-Unremarkable Sella, no enhancing pituitary mass Surgical Pathology-Gynecomastia, negative for atypia or malignancy - Abstract 108 Table 1
Time course of laboratory data
Day of admission 1 2 3 4 5 6 7 8 Absolute neutrophil count (cells/μL) 63 52 12 0 0 72 210 522 Free T4 (ng/dL) 1.8 1.8 2 2.5 3.3 4.5 3.7 3.3 Thyroid stimulating hormone (mIU/L) <0.004 <0.004 <0.004 <0.004 <0.004 <0.004 <0.004 <0.004 - Abstract 224 Table 1
Laboratory Values
POD 1 POD 2 POD 3 POD 4 POD 5 POD 6 Daily serum sodium (mmol/L) 135→129 133–135 134–137 130–134 137 131 Urine osmolality (mOsm/kg) 673 459 Urine sodium (mmol/L) 268 217 Urine output (mL/kg/hr) 1.9 10.6 19.4 4.1 4.7 3.8 Sodium intake (meq/kg/day) 11.1 43.7 60 22.7 20 20 Fluid balance (mL) 836 286 351 25 90 38 BNP (pg/mL) 271.6 16.1 - Abstract 234 Table 1
Mean NTproBNP level (SEM) at 28, 32 and 36 weeks GA in the BPD and control group
Gestational Age (weeks) Mean NTproBNP BPD group (pg/ml) Mean NTproBNP control group (pg/ml) p value 28 4034±1131 755±162 0.04 32 4434±1345 751±179 0.05 36 4814±1368 763±229 0.05 - Abstract 234 Table 2
Gestational Age (weeks) Mean NTproBNP PAH by ECHO (pg/ml) Mean NTproBNP No PAH by ECHO (pg/ml) p value 28 6210±2251 1603±482 0.006 32 7079±2768 1631±495 0.006 36 8190±2975 1953±633 0.004 - Abstract 282 Table 1
One sample t-test for ECHO results
% of patients with low abnormal Mean value Lowest normal value p-value SF 23.8 36.48 % 28 % EF 28.6 67.71 % 58 % LVEDD 38.1 1.66 cm 1.67 cm - Abstract 286 Table 1
NEONATAL OUTCOMES
OUTCOME IUGR+FPI+ELBW
n=23IUGR-FPI+ELBW
n=35AGA+ELBW
n=59Day 28 enteral, Kcal/Kg/day 53.3±47.9* 87.0±41.4 86.2±49.6 † 36 week enteral, Kcal/Kg/day 80.0±52.0 106.8±49.0 111.3±29.8 † TPN days 46.2±34.2* 46.2±34.2* 29.3±28.5 † BPD, n(%) 7(30) 21(60) 35(59) *p<0.05 IUGR+FPI vs IUGR-FPI; †p<0.05 IUGR+FPI vs AGA+ELBW
- Abstract 288 Table 1
Measurement of biochemical activity of TF's in AF samples
AF samples Samples stored at 4°C Samples frozen to - 20C° EGF 190±26.6 165±22.96 HGF 8953±805 7997±671 TGF- α 7.73±0.28 7.78±0.6 Eotaxin 4.23±0.61 4.49±0.77 IL-6 88.72±24.46 110±21.6 IL-8 129.6±26.68 164.1±43.67 IL1ra 70±15.01 94.91±18.74 IP-10 1636±377 1996±561.2 - Abstract 289 Table 1
Comparison of serum and transcutaneous bilirubin values
Term (n=39) 24 Hr. 48 Hr. 72 Hr. Mean Difference in mean from seum bili Serum Bili 11.4 11 11.3 11.2 0 Tcb-C 11.2 10.7 11.2 11 + 0.2 Tcb-U 5.8 5.4 4.9 5.4 + 5.8 Preterm (n=71) Serum Bili 9 8.2 7.7 8.3 0 Tcb-C 10.1 9 8.9 9.3 −1.0 Tcb-U 9.3 6.9 6.3 7.5 + 0.8 Extremely Preterm (n=15) Serum Bili 3.8 3.3 2.8 3.3 0 Tcb-C 7.3 7 5.8 6.7 −3.4 TcB-U 3.6 3 2.2 2.9 + 0.4 - Abstract 292 Table 1
PD related complications in both groups
Group Bowel obstruction Perforation Adhesion/Strictures Drain complications Others EL 0 1 0 0 1 PD 3 6 2 2 3 - Abstract 294 Table 1
iNO group (n=57) Control group (n= 455) p value Birth weight
(mean, SD)687, 240 958, 295 <0.001 Gestation
(mean, SD)25.5, 2 27.7, 2.7 <0.001 Afrian American race 96.4% 83.5% <0.01 Male sex 54.4% 49% NS SGA status 33.3% 26.2% NS Antenatal Steroids 96.5% 92.1% NS 5 minute APGAR<4 17.5% 12.1% NS Medically/surgically treated PDA 52.7% 19.1% <0.001 BPD (O2 at 36 weeks) 61.5% 17.6% <0.001 Death 22.8% 7.25% <0.001 BPD or Death 74.3% 26.5% <0.001 There was no difference in the incidence of ROP or NEC between the two groups
- Abstract 297 Table 1
Adjusted ORs for neonatal outcomes with initial postnatal hydrocortisone use over surgical ligation of PDA
Death or BPD 2.4 (0.6 - 9.7) 0.23 Need for ventilation at 36 weeks postconceptional age 0.6 (0.1 – 4.0) 0.60 - Abstract 308 Table 1
Percent Change in White Blood Cell count
Suspected NEC Definite NEC N 69 37 WBC (%) 5 (−30 – 35) −41 (−68 – −13)* AMC (%) −8 (−47 – 82) −31 (−79 – 4) ANC (%) 15 (−44 – 74) −64 (−90 – −26)* % change from baseline are represented as median (25th–75th)
*p<0.05, definite NEC vs. suspected NEC
- Abstract 320 Table 1
Study Period Feeding Type Frequency of Intolerance
(n,%)MBM DHM Formula DHM Other RTBW
(n=37)39% 55% 6% 1/37 (2.7%) 1/37 (2.7%) Growth Period
(n=37)36% 29% 35% 0% 3/37 (8.1%) Growth Period: DHM
(n=27)19% 71% 10% 0% 0% - Abstract 320 Table 2
Study Period Weight Change Head Change Under 2 kg
(g/kg/day)2 kg - Discharge
(g/day)
(cm/week)Growth Period
(n=37)17.1±3.0 30.0±7.4 0.9±0.2 Growth Period: DHM
(n=27)16.3±2.8 31.6±9.9 1.0±0.2 - Abstract 325 Table 1
N (Risk %) Crude HR (95% CI) Adjusted HR (95% CI) IVH Grade ≥ 1 35 (29.7) 1.48 (0.70–3.14) 1.42 (0.66–3.04) ≥ 2 18 (15.3) 3.29 (1.25–8.64) 2.98 (1.12–7.91) ≥ 3 13 (11.0) 3.90 (1.23–12.34) 3.50 (1.08–11.39) * Estimated from a Cox proportional hazards regression and adjusted for birth weight, antenatal steroid use, and APGAR score
† AKI entered into model as a time-dependent covariate
- Abstract 328 Table 1
Baseline data
Variable Body Cooling (n=25) Head Cooling (n=20) Body+Head Cooling (n=45) p-value Maternal Age (yrs) 25.3 +–5.6 25.56 +– 5.7 24.9 +– 5.3 0.33 Gestational Age (wks) 38.2 +– 1.8 37.6 +– 1.8 37.9 +– 1.8 0.28 Birthweight (kg) 3.34+–1.03 2.97 +– 0.54 3.13 +– 806.8 0.13 Apgar <5 at 5 min 16 (80%) 21 (84%) 37 (82%) 0.73 Worst pH <60 min 6.89 +– 0.18 6.91 +– 0.20 6.90 +– 0.19 0.73 Worst BE <60 min −20.77 +– 6.87 −18.17 +– 5.19 −19.46 +– 6.15 0.20 Cooling start (hrs) 3.55 +– 1.47 3.74 +– 1.63 3.65 +– 1.54 0.69 Seizures 12 (60%) 20 (80%) 32 (71%) 0.14 - Abstract 344 Table 1
Age – years (median)
Sex – (% male)52
81Race (%)
Non-Hispanic Whites
Non-Hispanic Blacks
Other
26
72
2Smoking History (%)
Current smoker
Former smoker
Average pack years
36
45
28Rheumatologic Conditions (n)
Rheumatoid Arthritis
Psoriasis
Hidradenitis Supprativa
Sarcoidosis
Polymyositis
Ankylosing Spondylitis
Other
14
10
7
5
2
1
3
- Article
- Cardiovascular Club I, 11:00 AM
- Adult Clinical Case Symposium, 11:45 AM
- Pediatric Clinical Case Symposium
- Case Reports in Cardiovascular Medicine, 2:00 PM
- Moving Your Clinical Case Presentation into a Published Manuscript, 2:45 PM
- Adolescent Medicine and Pediatrics, Joint Plenary Poster Session and Reception, 4:00 PM
- Adult Clinical Case, Joint Plenary Poster Session and Reception
- Allergy, Immunology, and Rheumatology, Joint Plenary Poster Session and Reception
- Cardiovascular, Joint Plenary Poster Session and Reception
- Endocrinology and Metabolism, Joint Plenary Poster Session and Reception
- Gastroenterology, Joint Plenary Poster Session and Reception
- Health Care Research and Quality Improvement, Joint Plenary Poster Session and Reception
- Hematology and Oncology, Joint Plenary Poster Session and Reception
- Infectious Disease, HIV, and AIDS, Joint Plenary Poster Session and Reception
- Medical Education, Medical Ethics, and Advocacy, Joint Plenary Poster Session and Reception
- Neurology and Neurobiology, Joint Plenary Poster Session and Reception
- Palliative Care, Joint Plenary Poster Session and Reception
- Pediatric Clinical Case, Joint Plenary Poster Session and Reception
- Perinatal Medicine, Joint Plenary Poster Session and Reception
- Pulmonary and Critical Care Medicine, Joint Plenary Poster Session and Reception
- Renal, Electrolyte and Hypertension, Joint Plenary Poster Session and Reception
- Figures & Data
- eLetters
- Info & Metrics